Journal ArticleDOI
Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial
Yohann Loriot,Kurt Miller,Cora N. Sternberg,Karim Fizazi,Johann S. de Bono,Simon Chowdhury,Celestia S. Higano,Sarah B. Noonberg,S. Holmstrom,Harry H. Mansbach,Frank Perabo,De Phung,Cristina Ivanescu,Konstantina Skaltsa,Konstantina Skaltsa,Tomasz M. Beer,Bertrand Tombal +16 more
Reads0
Chats0
TLDR
The mixed-effects model analyses showed significant treatment differences in change from baseline to week 61 with enzalutamide compared with placebo for most FACT-P endpoints and EQ-5D visual analogue scale.Citations
More filters
Journal ArticleDOI
Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer
Adam Sharp,Adam Sharp,Ilsa Coleman,Wei Yuan,Cynthia C. Sprenger,David Dolling,Daniel Nava Rodrigues,Joshua W. Russo,Ines Figueiredo,Claudia Bertan,George Seed,Ruth Riisnaes,Takuma Uo,Antje Neeb,Jonathan Welti,Colm Morrissey,Suzanne Carreira,Jun Luo,Peter S. Nelson,Peter S. Nelson,Steven P. Balk,Lawrence D. True,Johann S. de Bono,Johann S. de Bono,Stephen R. Plymate +24 more
TL;DR: It is demonstrated that AR-V7 protein is rarely expressed in primary PC but is frequently detected following androgen deprivation therapy, with further significant increase in expression following abiraterone acetate or enzalutamide therapy, which provides impetus to develop therapies that abrogate AR-v7 signaling.
Journal ArticleDOI
Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial.
Daniel Khalaf,Matti Annala,Sinja Taavitsainen,Sinja Taavitsainen,Daygen Finch,Conrad D. Oja,Joanna Vergidis,Muhammad Zulfiqar,Katherine Sunderland,Arun Azad,Christian Kollmannsberger,Bernhard J. Eigl,Krista Noonan,Deepa Wadhwa,Andrew Attwell,Bruce Keith,Susan Ellard,Lyly H. Le,Martin E. Gleave,Alexander W. Wyatt,Kim N. Chi +20 more
TL;DR: The data suggest that using a sequencing strategy of abiraterone acetate followed by enzalutamide provides the greatest clinical benefit in this multicentre, randomised, open-label, phase 2, crossover trial of metastatic castration-resistant prostate cancer.
Journal ArticleDOI
Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets
David C. Wedge,David C. Wedge,Gunes Gundem,Gunes Gundem,Thomas J. Mitchell,Dan J. Woodcock,Inigo Martincorena,Mohammed J. R. Ghori,Jorge Zamora,Adam Butler,Hayley C. Whitaker,Zsofia Kote-Jarai,Ludmil B. Alexandrov,Peter Van Loo,Peter Van Loo,Charles E. Massie,Charles E. Massie,Stefan C. Dentro,Stefan C. Dentro,Stefan C. Dentro,Anne Y. Warren,Clare Verrill,Daniel M. Berney,Nening Dennis,Sue Merson,Steve Hawkins,William Howat,Yong-Jie Lu,Adam Lambert,Jonathan Kay,Barbara Kremeyer,Katalin Karaszi,Hayley J. Luxton,Niedzica Camacho,Niedzica Camacho,Luke Marsden,S. Edwards,Lucy Matthews,Valeria Bo,Daniel Leongamornlert,Daniel Leongamornlert,Stuart McLaren,Anthony C. H. Ng,Yongwei Yu,Hongwei Zhang,Tokhir Dadaev,Sarah Thomas,Douglas F. Easton,Mahbubl Ahmed,Elizabeth Bancroft,Elizabeth Bancroft,Cyril Fisher,Naomi Livni,David Nicol,Simon Tavaré,Pelvender Gill,Christopher Greenman,Vincent Khoo,Nicholas van As,Pardeep Kumar,Chris Ogden,Declan Cahill,Alan Thompson,Erik Mayer,Edward Rowe,Tim Dudderidge,Vincent Gnanapragasam,Vincent Gnanapragasam,Nimish Shah,Keiran Raine,David T. Jones,Andrew Menzies,Lucy Stebbings,Jon W. Teague,Steven Hazell,Cathy Corbishley,Johann S. de Bono,Gerhardt Attard,William B. Isaacs,Tapio Visakorpi,Michael Fraser,Paul C. Boutros,Paul C. Boutros,Robert G. Bristow,Robert G. Bristow,Paul Workman,Chris Sander,Freddie C. Hamdy,Andrew Futreal,Ultan McDermott,Bissan Al-Lazikani,Andy G. Lynch,G. Steven Bova,Christopher S. Foster,Daniel Brewer,Daniel Brewer,Daniel Brewer,David E. Neal,David E. Neal,Colin Cooper,Colin Cooper,Rosalind A. Eeles,Rosalind A. Eeles +102 more
TL;DR: Joint analysis of new and previously published sequencing data for primary and metastatic prostate cancers identifies new candidate driver mutations and provides insights into disease progression and potential drug targets.
Journal ArticleDOI
Androgen receptor function and androgen receptor–targeted therapies in breast cancer: A review
TL;DR: In-depth understanding of AR and AR-related signaling pathways would improve the treatment strategies for AR-positive breast cancer and inform the development of AR-targeted therapies to improve survival outcome in patients with breast cancer.
Journal ArticleDOI
Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models
Mari I. Suominen,Katja M. Fagerlund,Jukka P. Rissanen,Yvonne Konkol,Jukka P. Morko,Z. Peng,Esa Alhoniemi,Salla K. Laine,Eva Corey,Dominik Mumberg,Karl Ziegelbauer,Sanna-Maria Käkönen,Jussi M. Halleen,Robert L. Vessella,Arne Scholz +14 more
TL;DR: Radium-223 therapy exhibits a dual targeting mode-of-action that induces tumor cell death and suppresses tumor-induced pathologic bone formation in tumor microenvironment of osseous CRPC growth in mice.
References
More filters
Journal ArticleDOI
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
Elizabeth Eisenhauer,P. Therasse,Jan Bogaerts,Lawrence H. Schwartz,Daniel J. Sargent,Robert Ford,Janet Dancey,S. Arbuck,S. Gwyther,Margaret M. Mooney,Larry Rubinstein,Lalitha K. Shankar,Lori E. Dodd,Robert M. Kaplan,Denis Lacombe,Jaap Verweij +15 more
TL;DR: The revised RECIST includes a new imaging appendix with updated recommendations on the optimal anatomical assessment of lesions, and a section on detection of new lesions, including the interpretation of FDG-PET scan assessment is included.
Journal Article
EuroQol : a new facility for the measurement of health-related quality of life
Journal ArticleDOI
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Ian F. Tannock,Ronald de Wit,William R. Berry,Jozsef Horti,Anna Pluzanska,Kim N. Chi,Stéphane Oudard,Christine Theodore,Nicholas D. James,Ingela Turesson,Mark Rosenthal,Mario A. Eisenberger +11 more
TL;DR: When given with prednisone, treatment with docetaxel every three weeks led to superior survival and improved rates of response in terms of pain, serum PSA level, and quality of life, as compared with mitoxantrone plusprednisone.
Journal ArticleDOI
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
Philip W. Kantoff,Celestia S. Higano,N. Shore,E. Roy Berger,Eric J. Small,David F. Penson,Charles H. Redfern,Anna C. Ferrari,Robert Dreicer,Robert B. Sims,Yi Xu,Mark W. Frohlich,Paul F. Schellhammer +12 more
TL;DR: The use of sipuleucel-T prolonged overall survival among men with metastatic castration-resistant prostate cancer and immune responses to the immunizing antigen were observed in patients who received sipuleUcel- T.
Journal ArticleDOI
Modeling Valuations for EuroQol Health States
TL;DR: The model presented in this article appears to predict the values of the states for which there are direct observations and, thus, can be used to interpolate values for theStates for which no direct observations exist.
Related Papers (5)
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher,Karim Fizazi,Fred Saad,Mary-Ellen Taplin,Cora N. Sternberg,Kurt Miller,Ronald de Wit,Peter F.A. Mulders,Kim N. Chi,Neal D. Shore,Andrew J. Armstrong,Thomas W. Flaig,Aude Flechon,Paul N. Mainwaring,Mark D. Fleming,John D. Hainsworth,Mohammad Hirmand,Bryan Selby,Lynn Seely,Johann S. de Bono,B Ch +20 more
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
Tomasz M. Beer,Andrew J. Armstrong,Dana E. Rathkopf,Yohann Loriot,Cora N. Sternberg,Celestia S. Higano,Peter Iversen,Suman Bhattacharya,Joan Carles,Simon Chowdhury,Ian D. Davis,Johann S. de Bono,Christopher P. Evans,Karim Fizazi,Anthony M. Joshua,Choung-Soo Kim,Go Kimura,Paul N. Mainwaring,Harry H. Mansbach,Kurt Miller,Sarah B. Noonberg,Frank Perabo,De Phung,Fred Saad,Howard I. Scher,Mary-Ellen Taplin,Peter Venner,Bertrand Tombal +27 more
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Charles J. Ryan,Matthew R. Smith,Johann S. de Bono,Arturo Molina,Christopher J. Logothetis,Paul de Souza,Karim Fizazi,Paul N. Mainwaring,Josep M. Piulats,Siobhan Ng,Joan Carles,Peter F.A. Mulders,Ethan Basch,Eric J. Small,Fred Saad,D. Schrijvers,Hendrik Van Poppel,Som D. Mukherjee,Henrik Suttmann,Winald R. Gerritsen,Thomas W. Flaig,Daniel J. George,Evan Y. Yu,Eleni Efstathiou,Allan J. Pantuck,Eric Winquist,Celestia S. Higano,Mary-Ellen Taplin,Youn C. Park,Thian Kheoh,Thomas W. Griffin,Howard I. Scher,Dana E. Rathkopf +32 more
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. de Bono,Christopher J. Logothetis,Arturo Molina,Karim Fizazi,Scott North,Luis Chu,Kim N. Chi,Robert Jones,Oscar B. Goodman,Fred Saad,John Staffurth,Paul N. Mainwaring,S. J. Harland,Thomas W. Flaig,Thomas E. Hutson,Tina Cheng,Helen Patterson,John D. Hainsworth,Charles J. Ryan,Cora N. Sternberg,Susan Ellard,Aude Flechon,Mansoor N. Saleh,Mark C. Scholz,Eleni Efstathiou,Andrea Zivi,Diletta Bianchini,Yohann Loriot,Nicole Chieffo,Thian Kheoh,Christopher M. Haqq,Howard I. Scher +31 more